Description

Zimmer Biomet: What Is Powering The Surge In Robotics, Navigation, And Connected Orthopedic Care?

Zimmer Biomet began 2026 with solid operational execution, supported by improving product adoption trends, accelerating technology sales, disciplined margin management, and continued progress in its multiyear commercial transformation strategy. Organic constant currency revenue grew 2.9%, landing at the upper end of the company’s annual growth guidance range, while adjusted earnings per share increased more than 15% year-over-year. Revenue growth was supported by healthy reconstructive procedure demand, strong adoption of recently launched technologies, and robust momentum across robotics, data-driven surgical platforms, and specialized orthopedic products. Management also raised adjusted earnings per share and free cash flow growth expectations for the full year following better-than-expected first-quarter profitability and favorable tariff-related developments. The company’s technology and data segment continued to emerge as an important growth contributor. Technology, data, bone cement, and surgical sales increased nearly 12%, while robotic-related sales growth exceeded 30% during the quarter.